Skip to main content

Table 2 Complications noted and use of antibiotics in influenza-infected patients

From: Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews

Trial

Southern Hemisphere (NAIB3001)

Europe (NAIB3002)

North America (NAIA3002)

Complications

Placebo

30%

33%

22%

Zanamivir

24%

24%

15%

P value

0.24

0.125

0.049*

Antibiotics use

Placebo

28%

17%

15%

Zanamivir

26%

11%

11%

P value

0.58

0.21

0.16

  1. *P < 0.05